{"drugs":["Hydrocodone Bitartrate\/Ibuprofen","Ibudone","Reprexain","Vicoprofen"],"mono":{"0":{"id":"924365-s-0","title":"Generic Names","mono":"Hydrocodone Bitartrate\/Ibuprofen"},"1":{"id":"924365-s-1","title":"Dosing and Indications","sub":[{"id":"924365-s-1-4","title":"Adult Dosing","mono":"<ul><li>use lowest effective dose for shortest possible duration<\/li><li><b>Pain, acute:<\/b> 1 tablet (hydrocodone bitartrate 2.5 mg to 10 mg\/ibuprofen 200 mg) ORALLY every 4 to 6 hours as needed; MAX 5 tablets in a 24-hour period; generally for less than 10 days<\/li><\/ul>"},{"id":"924365-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>use lowest effective dose for shortest possible duration<\/li><li>safety and efficacy not established for patients younger than 16 years<\/li><li><b>Pain, acute:<\/b> 16 years or older, 1 tablet (hydrocodone bitartrate 2.5 mg to 10 mg\/ibuprofen 200 mg) ORALLY every 4 to 6 hours as needed; MAX 5 tablets in a 24-hour period; generally for less than 10 days<\/li><\/ul>"},{"id":"924365-s-1-6","title":"Dose Adjustments","mono":"<b>geriatric:<\/b> use reduced dosages "},{"id":"924365-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Pain, acute<br\/><b>Non-FDA Labeled Indications<\/b><br\/>Pain, chronic<br\/>"}]},"3":{"id":"924365-s-3","title":"Contraindications\/Warnings","sub":[{"id":"924365-s-3-9","title":"Contraindications","mono":"<ul><li>coronary artery bypass graft (CABG) surgery, treatment of peri-operative pain; increased incidence of myocardial infarction and stroke<\/li><li>hypersensitivity to ibuprofen, hydrocodone, or any product ingredient<\/li><li>hypersensitivity to other opioids; cross-sensitivity reaction possible<\/li><li>asthma, urticaria, or allergic-type reactions following aspirin or other nonsteroidal anti-inflammatory agents; severe, even fatal, anaphylactic-like reactions have been reported<\/li><\/ul>"},{"id":"924365-s-3-10","title":"Precautions","mono":"<ul><li>cardiovascular disease, known or risk factors for; increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke; risk may increase with duration of use<\/li><li>cardiovascular thrombotic events including myocardial infarction, stroke, and fatalities may occur<\/li><li>elderly or debilitated patients; increased risk of gastrointestinal injury, including fatal events; increased risk of renal toxicity and injury; respiratory depression may occur<\/li><li>gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal may occur<\/li><li>abdominal conditions, acute; diagnosis or clinical course may be obscured<\/li><li>abuse, misuse, diversion, and dependence potential<\/li><li>Addison's disease;  respiratory depression may occur<\/li><li>alcohol use or smoking; increased risk of gastrointestinal injury<\/li><li>aseptic meningitis risk<\/li><li>aspirin triad (bronchospasm in asthmatic patients with rhinitis, with or without nasal polyps following aspirin or non-steroidal antiinflammatory administration); increased risk of anaphylactoid reaction<\/li><li>asthma, especially with history of aspirin-sensitive asthma; severe bronchospasm and fatalities may occur<\/li><li>coagulation disorder; bleeding time may be prolonged<\/li><li>concurrent use with oral corticosteroids; increased risk of serious gastrointestinal events<\/li><li>concurrent use of ACE inhibitors; increased risk of renal toxicity and injury<\/li><li>concurrent use with aspirin or anticoagulants; increased risk of serious gastrointestinal events; bleeding time may be prolonged<\/li><li>concurrent use of thiazide or loop-diuretics; increased risk of renal toxicity and injury<\/li><li>fluid retention or heart failure; may lead to new or worsening symptoms<\/li><li>gastrointestinal bleeding; increased risk of bleeding, ulceration or perforation of the stomach or intestines, and fatalities<\/li><li>head injury, intracranial lesions, or increased intracranial pressure; may elevate cerebrospinal fluid pressure resulting in excessive respiratory depression; adverse reactions to opioid may obscure clinical course of head injury<\/li><li>heart failure; increased risk of renal toxicity and injury<\/li><li>high doses; increased risk of irregular, periodic breathing, and respiratory depression<\/li><li>hypertension; increased risk of new or worsening symptoms<\/li><li>hypothyroidism; respiratory depression may occur<\/li><li>liver dysfunction; increased risk of renal toxicity and injury; respiratory depression may occur; increased risk of severe, possibly fatal, hepatic reactions<\/li><li>long-term use; increased risk of gastrointestinal or renal injury; anemia may occur<\/li><li>poor general health; increased risk of gastrointestinal injury<\/li><li>pregnancy, third trimester use; premature close of ductus arteriosus may occur<\/li><li>prostatic hypertrophy or urethral stricture; respiratory depression may occur<\/li><li>pulmonary disease, postoperative use; suppresses the cough reflex;<\/li><li>renal disease or impairment; increased risk of renal toxicity and injury may occur<\/li><li>skin reactions; serious adverse events including exfoliative dermatitis, Stevens Johnson syndrome, toxic epidermal necrolysis, and fatalities may occur<\/li><li>systemic lupus erythematosus and related connective tissue disease; increased risk of aseptic meningitis with fever and coma<\/li><li>ulcer disease, history of; greater than 10-fold increased risk for gastrointestinal bleeding<\/li><\/ul>"},{"id":"924365-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"924365-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"924365-s-4","title":"Drug Interactions","sub":[{"id":"924365-s-4-13","title":"Contraindicated","mono":"<ul><li>Ketorolac (theoretical)<\/li><li>Naltrexone (probable)<\/li><\/ul>"},{"id":"924365-s-4-14","title":"Major","mono":"<ul><li>Abciximab (theoretical)<\/li><li>Abiraterone (theoretical)<\/li><li>Acetophenazine (theoretical)<\/li><li>Alfentanil (theoretical)<\/li><li>Alprazolam (theoretical)<\/li><li>Amobarbital (theoretical)<\/li><li>Amprenavir (theoretical)<\/li><li>Anagrelide (theoretical)<\/li><li>Anileridine (theoretical)<\/li><li>Apixaban (theoretical)<\/li><li>Aprepitant (theoretical)<\/li><li>Aprobarbital (theoretical)<\/li><li>Ardeparin (probable)<\/li><li>Argatroban (theoretical)<\/li><li>Aspirin (probable)<\/li><li>Atazanavir (theoretical)<\/li><li>Baclofen (probable)<\/li><li>Beta Glucan (theoretical)<\/li><li>Bivalirudin (theoretical)<\/li><li>Boceprevir (theoretical)<\/li><li>Bosentan (theoretical)<\/li><li>Bromazepam (theoretical)<\/li><li>Brotizolam (theoretical)<\/li><li>Buprenorphine (probable)<\/li><li>Buspirone (theoretical)<\/li><li>Butabarbital (theoretical)<\/li><li>Butalbital (theoretical)<\/li><li>Butorphanol (probable)<\/li><li>Carbamazepine (theoretical)<\/li><li>Carbinoxamine (theoretical)<\/li><li>Carisoprodol (probable)<\/li><li>Ceritinib (theoretical)<\/li><li>Certoparin (probable)<\/li><li>Chloral Hydrate (theoretical)<\/li><li>Chlordiazepoxide (theoretical)<\/li><li>Chlorpromazine (theoretical)<\/li><li>Chlorzoxazone (probable)<\/li><li>Cilostazol (theoretical)<\/li><li>Ciprofloxacin (theoretical)<\/li><li>Citalopram (probable)<\/li><li>Clarithromycin (theoretical)<\/li><li>Clobazam (theoretical)<\/li><li>Clonazepam (theoretical)<\/li><li>Clopidogrel (probable)<\/li><li>Clorazepate (theoretical)<\/li><li>Clovoxamine (probable)<\/li><li>Cobicistat (theoretical)<\/li><li>Codeine (theoretical)<\/li><li>Conivaptan (theoretical)<\/li><li>Crizotinib (theoretical)<\/li><li>Cyclobenzaprine (theoretical)<\/li><li>Cyclosporine (established)<\/li><li>Dabigatran Etexilate (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Dalteparin (probable)<\/li><li>Danaparoid (probable)<\/li><li>Dantrolene (probable)<\/li><li>Darunavir (theoretical)<\/li><li>Delavirdine (theoretical)<\/li><li>Desirudin (theoretical)<\/li><li>Dexamethasone (theoretical)<\/li><li>Dexmedetomidine (theoretical)<\/li><li>Dezocine (probable)<\/li><li>Diacetylmorphine (theoretical)<\/li><li>Diazepam (theoretical)<\/li><li>Difenoxin (theoretical)<\/li><li>Dihydrocodeine (theoretical)<\/li><li>Diltiazem (theoretical)<\/li><li>Diphenhydramine (theoretical)<\/li><li>Diphenoxylate (theoretical)<\/li><li>Dipyridamole (theoretical)<\/li><li>Dixyrazine (theoretical)<\/li><li>Donepezil (theoretical)<\/li><li>Doxylamine (theoretical)<\/li><li>Dronedarone (theoretical)<\/li><li>Duloxetine (probable)<\/li><li>Edoxaban (established)<\/li><li>Efavirenz (theoretical)<\/li><li>Enoxaparin (probable)<\/li><li>Enzalutamide (theoretical)<\/li><li>Eptifibatide (theoretical)<\/li><li>Erlotinib (theoretical)<\/li><li>Erythromycin (theoretical)<\/li><li>Escitalopram (probable)<\/li><li>Eslicarbazepine Acetate (theoretical)<\/li><li>Estazolam (theoretical)<\/li><li>Eszopiclone (theoretical)<\/li><li>Ethchlorvynol (theoretical)<\/li><li>Ethopropazine (theoretical)<\/li><li>Ethylmorphine (theoretical)<\/li><li>Etravirine (theoretical)<\/li><li>Femoxetine (probable)<\/li><li>Fentanyl (theoretical)<\/li><li>Feverfew (theoretical)<\/li><li>Flesinoxan (probable)<\/li><li>Fluconazole (theoretical)<\/li><li>Flunitrazepam (theoretical)<\/li><li>Fluoxetine (probable)<\/li><li>Fluphenazine (theoretical)<\/li><li>Flurazepam (theoretical)<\/li><li>Fondaparinux (theoretical)<\/li><li>Fosamprenavir (theoretical)<\/li><li>Fosaprepitant (theoretical)<\/li><li>Fosphenytoin (theoretical)<\/li><li>Fospropofol (theoretical)<\/li><li>Furazolidone (probable)<\/li><li>Ginkgo (probable)<\/li><li>Gossypol (theoretical)<\/li><li>Halazepam (theoretical)<\/li><li>Heparin (theoretical)<\/li><li>Hexobarbital (theoretical)<\/li><li>Hydromorphone (theoretical)<\/li><li>Hydroxyzine (theoretical)<\/li><li>Idelalisib (theoretical)<\/li><li>Imatinib (theoretical)<\/li><li>Indinavir (theoretical)<\/li><li>Iproniazid (probable)<\/li><li>Isocarboxazid (probable)<\/li><li>Itraconazole (theoretical)<\/li><li>Ketazolam (theoretical)<\/li><li>Ketobemidone (theoretical)<\/li><li>Ketoconazole (theoretical)<\/li><li>Lepirudin (theoretical)<\/li><li>Levomilnacipran (theoretical)<\/li><li>Levorphanol (theoretical)<\/li><li>Linezolid (probable)<\/li><li>Lomitapide (theoretical)<\/li><li>Lopinavir (theoretical)<\/li><li>Lorazepam (theoretical)<\/li><li>Lormetazepam (theoretical)<\/li><li>Loxapine (theoretical)<\/li><li>Meadowsweet (theoretical)<\/li><li>Meclizine (theoretical)<\/li><li>Medazepam (theoretical)<\/li><li>Meperidine (theoretical)<\/li><li>Mephenesin (probable)<\/li><li>Mephobarbital (theoretical)<\/li><li>Meprobamate (probable)<\/li><li>Meptazinol (probable)<\/li><li>Mesoridazine (theoretical)<\/li><li>Metaxalone (probable)<\/li><li>Methadone (theoretical)<\/li><li>Methdilazine (theoretical)<\/li><li>Methocarbamol (probable)<\/li><li>Methohexital (theoretical)<\/li><li>Methotrexate (probable)<\/li><li>Methotrimeprazine (theoretical)<\/li><li>Methylene Blue (probable)<\/li><li>Metopimazine (theoretical)<\/li><li>Miconazole (theoretical)<\/li><li>Midazolam (theoretical)<\/li><li>Mifepristone (theoretical)<\/li><li>Milnacipran (probable)<\/li><li>Mitotane (theoretical)<\/li><li>Moclobemide (probable)<\/li><li>Modafinil (theoretical)<\/li><li>Morphine (theoretical)<\/li><li>Morphine Sulfate Liposome (theoretical)<\/li><li>Nadroparin (probable)<\/li><li>Nafcillin (theoretical)<\/li><li>Nalbuphine (probable)<\/li><li>Nefazodone (probable)<\/li><li>Nelfinavir (theoretical)<\/li><li>Nevirapine (theoretical)<\/li><li>Nicomorphine (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Nitisinone (theoretical)<\/li><li>Nitrazepam (theoretical)<\/li><li>Opium (theoretical)<\/li><li>Opium Alkaloids (theoretical)<\/li><li>Orphenadrine (probable)<\/li><li>Oxazepam (theoretical)<\/li><li>Oxcarbazepine (theoretical)<\/li><li>Oxycodone (theoretical)<\/li><li>Oxymorphone (theoretical)<\/li><li>Papaveretum (theoretical)<\/li><li>Paregoric (theoretical)<\/li><li>Parnaparin (probable)<\/li><li>Paroxetine (probable)<\/li><li>Pemetrexed (theoretical)<\/li><li>Pentazocine (probable)<\/li><li>Pentobarbital (theoretical)<\/li><li>Pentosan Polysulfate Sodium (theoretical)<\/li><li>Pentoxifylline (theoretical)<\/li><li>Perampanel (theoretical)<\/li><li>Perazine (theoretical)<\/li><li>Periciazine (theoretical)<\/li><li>Perphenazine (theoretical)<\/li><li>Phenelzine (probable)<\/li><li>Phenobarbital (theoretical)<\/li><li>Phenytoin (theoretical)<\/li><li>Piperaquine (theoretical)<\/li><li>Pipotiazine (theoretical)<\/li><li>Piritramide (theoretical)<\/li><li>Posaconazole (theoretical)<\/li><li>Pralatrexate (theoretical)<\/li><li>Prasugrel (theoretical)<\/li><li>Prazepam (theoretical)<\/li><li>Prednisolone (theoretical)<\/li><li>Prednisone (theoretical)<\/li><li>Primidone (theoretical)<\/li><li>Procarbazine (probable)<\/li><li>Prochlorperazine (theoretical)<\/li><li>Promazine (theoretical)<\/li><li>Promethazine (theoretical)<\/li><li>Propiomazine (theoretical)<\/li><li>Propofol (theoretical)<\/li><li>Protein C (theoretical)<\/li><li>Quazepam (theoretical)<\/li><li>Ramelteon (theoretical)<\/li><li>Rasagiline (probable)<\/li><li>Regorafenib (theoretical)<\/li><li>Remifentanil (theoretical)<\/li><li>Reviparin (probable)<\/li><li>Rifabutin (theoretical)<\/li><li>Rifampin (theoretical)<\/li><li>Rifapentine (theoretical)<\/li><li>Ritonavir (theoretical)<\/li><li>Rivaroxaban (theoretical)<\/li><li>Saquinavir (theoretical)<\/li><li>Secobarbital (theoretical)<\/li><li>Selegiline (probable)<\/li><li>Sibutramine (theoretical)<\/li><li>Siltuximab (theoretical)<\/li><li>Sodium Oxybate (theoretical)<\/li><li>St John's Wort (theoretical)<\/li><li>Sufentanil (theoretical)<\/li><li>Suvorexant (theoretical)<\/li><li>Tacrolimus (probable)<\/li><li>Tapentadol (theoretical)<\/li><li>Telaprevir (theoretical)<\/li><li>Telithromycin (theoretical)<\/li><li>Temazepam (theoretical)<\/li><li>Thiethylperazine (theoretical)<\/li><li>Thiopental (theoretical)<\/li><li>Thiopropazate (theoretical)<\/li><li>Thioproperazine (theoretical)<\/li><li>Thioridazine (theoretical)<\/li><li>Ticagrelor (theoretical)<\/li><li>Ticlopidine (theoretical)<\/li><li>Tilidine (theoretical)<\/li><li>Tinzaparin (probable)<\/li><li>Tipranavir (theoretical)<\/li><li>Tirofiban (theoretical)<\/li><li>Tizanidine (probable)<\/li><li>Topiramate (theoretical)<\/li><li>Tramadol (theoretical)<\/li><li>Tranylcypromine (probable)<\/li><li>Triazolam (theoretical)<\/li><li>Triflupromazine (theoretical)<\/li><li>Trimeprazine (theoretical)<\/li><li>Venlafaxine (probable)<\/li><li>Verapamil (theoretical)<\/li><li>Vilazodone (theoretical)<\/li><li>Voriconazole (theoretical)<\/li><li>Vortioxetine (theoretical)<\/li><li>Zaleplon (theoretical)<\/li><li>Zimeldine (probable)<\/li><li>Zolpidem (theoretical)<\/li><li>Zopiclone (theoretical)<\/li><\/ul>"},{"id":"924365-s-4-15","title":"Moderate","mono":"<ul><li>Acebutolol (probable)<\/li><li>Alacepril (established)<\/li><li>Alprenolol (probable)<\/li><li>Amikacin (probable)<\/li><li>Amiloride (probable)<\/li><li>Amlodipine (probable)<\/li><li>Arotinolol (probable)<\/li><li>Atenolol (probable)<\/li><li>Azilsartan (probable)<\/li><li>Azilsartan Medoxomil (probable)<\/li><li>Azosemide (probable)<\/li><li>Befunolol (probable)<\/li><li>Bemetizide (probable)<\/li><li>Benazepril (established)<\/li><li>Bendroflumethiazide (probable)<\/li><li>Benzthiazide (probable)<\/li><li>Bepridil (probable)<\/li><li>Betaxolol (probable)<\/li><li>Bevantolol (probable)<\/li><li>Bisoprolol (probable)<\/li><li>Bopindolol (probable)<\/li><li>Bucindolol (probable)<\/li><li>Bumetanide (probable)<\/li><li>Bupranolol (probable)<\/li><li>Buthiazide (probable)<\/li><li>Candesartan Cilexetil (probable)<\/li><li>Canrenoate (probable)<\/li><li>Captopril (established)<\/li><li>Carteolol (probable)<\/li><li>Carvedilol (probable)<\/li><li>Celiprolol (probable)<\/li><li>Chlorothiazide (probable)<\/li><li>Chlorpropamide (probable)<\/li><li>Chlorthalidone (probable)<\/li><li>Cilazapril (established)<\/li><li>Clopamide (probable)<\/li><li>Cyclopenthiazide (probable)<\/li><li>Delapril (established)<\/li><li>Desipramine (probable)<\/li><li>Desvenlafaxine (probable)<\/li><li>Dilevalol (probable)<\/li><li>Enalapril (established)<\/li><li>Enalaprilat (established)<\/li><li>Eprosartan (probable)<\/li><li>Esmolol (probable)<\/li><li>Ethacrynic Acid (probable)<\/li><li>Felodipine (probable)<\/li><li>Flunarizine (probable)<\/li><li>Fosinopril (established)<\/li><li>Furosemide (probable)<\/li><li>Gallopamil (probable)<\/li><li>Glimepiride (probable)<\/li><li>Glipizide (probable)<\/li><li>Glyburide (probable)<\/li><li>Hydrochlorothiazide (probable)<\/li><li>Hydroflumethiazide (probable)<\/li><li>Imidapril (established)<\/li><li>Indapamide (probable)<\/li><li>Irbesartan (probable)<\/li><li>Isradipine (probable)<\/li><li>Labetalol (probable)<\/li><li>Lacidipine (probable)<\/li><li>Landiolol (probable)<\/li><li>Levobunolol (probable)<\/li><li>Lidoflazine (probable)<\/li><li>Lisinopril (established)<\/li><li>Lithium (probable)<\/li><li>Losartan (probable)<\/li><li>Manidipine (probable)<\/li><li>Mepindolol (probable)<\/li><li>Methyclothiazide (probable)<\/li><li>Metipranolol (probable)<\/li><li>Metolazone (probable)<\/li><li>Metoprolol (probable)<\/li><li>Moexipril (established)<\/li><li>Nadolol (probable)<\/li><li>Nateglinide (probable)<\/li><li>Nebivolol (probable)<\/li><li>Nicardipine (probable)<\/li><li>Nifedipine (probable)<\/li><li>Nilvadipine (probable)<\/li><li>Nimodipine (probable)<\/li><li>Nipradilol (probable)<\/li><li>Nisoldipine (probable)<\/li><li>Nitrendipine (probable)<\/li><li>Olmesartan Medoxomil (probable)<\/li><li>Oxprenolol (probable)<\/li><li>Penbutolol (probable)<\/li><li>Pentopril (established)<\/li><li>Perindopril (established)<\/li><li>Pindolol (probable)<\/li><li>Piretanide (probable)<\/li><li>Polythiazide (probable)<\/li><li>Pranidipine (probable)<\/li><li>Propranolol (probable)<\/li><li>Quinapril (established)<\/li><li>Ramipril (established)<\/li><li>Repaglinide (probable)<\/li><li>Sotalol (probable)<\/li><li>Spirapril (established)<\/li><li>Spironolactone (probable)<\/li><li>Tacrine (probable)<\/li><li>Talinolol (probable)<\/li><li>Tasosartan (probable)<\/li><li>Telmisartan (probable)<\/li><li>Temocapril (established)<\/li><li>Tertatolol (probable)<\/li><li>Timolol (probable)<\/li><li>Tolazamide (probable)<\/li><li>Tolbutamide (probable)<\/li><li>Torsemide (probable)<\/li><li>Trandolapril (established)<\/li><li>Triamterene (probable)<\/li><li>Trichlormethiazide (probable)<\/li><li>Valsartan (probable)<\/li><li>Xipamide (probable)<\/li><li>Zofenopril (established)<\/li><\/ul>"}]},"5":{"id":"924365-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Constipation (22%), Indigestion (12%), Nausea (21%)<\/li><li><b>Hepatic:<\/b>Increased liver function test (up to 15%)<\/li><li><b>Neurologic:<\/b>Dizziness (14%), Headache (27%), Somnolence (22%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Congestive heart failure, Edema (3% to 9%), Hypertension, Myocardial infarction, Thrombotic tendency observations<\/li><li><b>Dermatologic:<\/b>Scaling eczema, Stevens-Johnson syndrome, Toxic epidermal necrolysis<\/li><li><b>Gastrointestinal:<\/b>Gastrointestinal hemorrhage, Gastrointestinal perforation, Gastrointestinal ulcer, Inflammatory disorder of digestive tract<\/li><li><b>Hepatic:<\/b>Hepatitis, Jaundice, Liver failure<\/li><li><b>Immunologic:<\/b>Anaphylactoid reaction<\/li><li><b>Neurologic:<\/b>Cerebrovascular accident, Raised intracranial pressure<\/li><li><b>Renal:<\/b>Acute renal failure<\/li><li><b>Respiratory:<\/b>Bronchospasm, Respiratory depression<\/li><\/ul>"},"6":{"id":"924365-s-6","title":"Drug Name Info","sub":{"0":{"id":"924365-s-6-17","title":"US Trade Names","mono":"<ul><li>Reprexain<\/li><li>Vicoprofen<\/li><li>Ibudone<\/li><\/ul>"},"2":{"id":"924365-s-6-19","title":"Class","mono":"<ul><li>NSAID<\/li><li>Opioid<\/li><li>Opioid\/NSAID Combination<\/li><li>Propionic Acid (class)<\/li><\/ul>"},"3":{"id":"924365-s-6-20","title":"Regulatory Status","mono":"Schedule II<br\/>"},"4":{"id":"924365-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"924365-s-7","title":"Mechanism Of Action","mono":"<ul><li>Systemic: Hydrocodone-The exact mechanism of action of hydrocodone is unknown . Hydrocodone is an opioid analgesic . It has been proposed that opioid analgesics bind with specific opioid receptors at many sites in the central nervous system (CNS) to alter processes affecting pain sensation .<\/li><li>Ibuprofen-Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic therapeutic effects . The exact mechanism of action of ibuprofen has not been determined . However, it has been proposed that ibuprofen, like other NSAIDs, inhibits the activity of the enzyme cyclo-oxygenase, resulting in a decreased formation of precursors of prostaglandins . The resulting decrease in prostaglandin synthesis may be responsible for the therapeutic effects of ibuprofen .<\/li><\/ul>"},"8":{"id":"924365-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"924365-s-8-23","title":"Absorption","mono":"Systemic: Rapid    <br\/>"},"2":{"id":"924365-s-8-25","title":"Metabolism","mono":"<ul><li>Systemic: Hydrocodone- Hepatic: extensive via CYP2D6 and CYP3A4 pathways; Metabolites: hydroxy metabolites; Active metabolite: hydromorphone    <\/li><li>Ibuprofen- Hepatic: Metabolites: phenyl proprionic acid metabolites    <\/li><\/ul>"},"3":{"id":"924365-s-8-26","title":"Excretion","mono":"<ul><li>Systemic: Hydrocodone- Renal   <\/li><li>Ibuprofen- Renal: 50 to 60% as metabolites; 15% as unchanged and conjugate   <\/li><\/ul>"},"4":{"id":"924365-s-8-27","title":"Elimination Half Life","mono":"<ul><li>Systemic: Hydrocodone: 4.5 h    <\/li><li>Ibuprofen: 2.2 h    <\/li><\/ul>"}}},"10":{"id":"924365-s-10","title":"Monitoring","mono":"<ul><li>pain reduction, improvement in ability to move<\/li><li>CBC, blood pressure, fecal occult blood test, and liver function tests; monitor after initiation of NSAID therapy and every 6-12 months thereafter, more frequently in patients at risk for hepatic, renal, cardiac, or gastrointestinal toxicity (eg: age greater than 60 years old, high-dose NSAID therapy, concurrent corticosteroids or anticoagulants, history of cardiac, renal, or hepatic disease)<\/li><li>mental and respiratory status<\/li><li>bowel movements<\/li><li>signs and symptoms of withdrawal<\/li><\/ul>"},"11":{"id":"924365-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/>Oral Tablet: (Hydrocodone Bitartrate - Ibuprofen) 2.5 MG-200 MG, 5 MG-200 MG, 7.5 MG-200 MG, 10 MG-200 MG<br\/><\/li><li><b>Ibudone<\/b><br\/>Oral Tablet: (Hydrocodone Bitartrate - Ibuprofen) 5 MG-200 MG, 10 MG-200 MG<br\/><\/li><li><b>Reprexain<\/b><br\/>Oral Tablet: (Hydrocodone Bitartrate - Ibuprofen) 2.5 MG-200 MG, 5 MG-200 MG, 10 MG-200 MG<br\/><\/li><li><b>Vicoprofen<\/b><br\/>Oral Tablet: (Hydrocodone Bitartrate - Ibuprofen) 7.5 MG-200 MG<br\/><\/li><li><b>Xylon 10<\/b><br\/>Oral Tablet: (Hydrocodone Bitartrate - Ibuprofen) 10 MG-200 MG<br\/><\/li><\/ul>"},"12":{"id":"924365-s-12","title":"Toxicology","sub":[{"id":"924365-s-12-31","title":"Clinical Effects","mono":"<ul><li><b>HYDROCODONE<\/b><br\/>USES: Hydrocodone is used for the treatment of pain, and for cough suppression. Hydrocodone may be abused for euphoric effects by multiple routes (i.e., injection, insufflation, ingestion). It is available in combination products with acetaminophen, ibuprofen, and mucolytics\/expectorants. It is also available as a sustained release formulation. EPIDEMIOLOGY: Overdose is fairly common, particularly in patients with chronic opioid abuse, and may be life threatening. PHARMACOLOGY: Hydrocodone is a semisynthetic derivative of codeine, that binds at the opiate receptor. TOXICOLOGY: Therapeutic and toxic effects are mediated by different opioid receptors. Mu 1: Supraspinal and peripheral analgesia, sedation, and euphoria. Mu 2: Spinal analgesia, respiratory depression, physical dependence, GI dysmotility, bradycardia and pruritus. Kappa 1: Spinal analgesia and miosis. Kappa 2: Dysphoria and psychotomimesis. Kappa 3: Supraspinal analgesia. Chronic opioid users develop tolerance to the analgesic and euphoric effects, but not to the respiratory depression effects. OVERDOSE: MILD TO MODERATE POISONING: Euphoria, drowsiness, constipation, nausea, vomiting and pinpoint pupils. Mild bradycardia or hypotension may be present. SEVERE POISONING: Respiratory depression leading to apnea, hypoxia, coma, bradycardia, or acute lung injury. Rarely, seizures may develop from hypoxia. Death may result from any of these complications.<br\/><\/li><li><b>IBUPROFEN <\/b><br\/>USES: Ibuprofen is used for fever and pain control and for the treatment of several rheumatologic conditions. PHARMACOLOGY: Ibuprofen inhibits the cyclooxygenase enzyme, leading to decreased prostaglandin production and decreased pain and inflammation. TOXICOLOGY: Gastrointestinal (GI) symptoms are due to both local irritant effects and the inhibition of prostaglandins (PG), which are responsible in part for maintaining the GI mucosal barrier. Inhibition of thromboxane A2 production in platelets prolongs bleeding time and contributes to gastrointestinal bleeding. Inhibition of PGI2 and PGE2, which have vasodilatory and natriuretic activity in the kidney, can be linked to sodium and water retention and occasional acute renal failure. EPIDEMIOLOGY: Overdose is common; however, severe toxicity is very rare. MILD TO MODERATE TOXICITY: In general, patients are asymptomatic or have mild GI upset (ie, nausea, vomiting, abdominal pain). Mild CNS depression (drowsiness, lethargy) and headache are common (incidence up to 30%). Nystagmus, diplopia, headache, tinnitus, and transient deafness may also occur following overdose. SEVERE TOXICITY: With massive overdose, seizure, coma, acute renal failure, and, very rarely, cardiopulmonary arrest may occur. Upper GI bleeding may occur after acute or chronic ingestion. Elevated liver enzymes, hypoprothrombinemia, metabolic acidosis, hypokalemia, hypophosphatemia, hyponatremia, and hyperkalemia (associated with renal failure), hypotension, bradycardia, tachycardia, atrial fibrillation, dyspnea, aspiration pneumonia, rhabdomyolysis, and disseminated intravascular coagulation have also been observed in overdose. Transient episodes of apnea have been reported in young children following large ingestions. Acute pancreatitis has been reported. ONSET: Symptoms typically occur within 4 to 6 hours of ingestion. ADVERSE EFFECTS: Gastrointestinal distress, nausea, and epigastric pain are the most common findings; upper GI bleeding may occur after acute or chronic ingestion. Angioedema, hives, itching, rash, and swelling have also been reported with therapeutic use. Fluid retention, interstitial nephritis, nephritic syndrome, and acute renal failure can develop. Hematologic effects include agranulocytosis, aplastic anemia, and thrombocytopenia. Headache, asthma exacerbation, aseptic meningitis, delirium, and anaphylactoid reactions have also been reported.<br\/><\/li><\/ul>"},{"id":"924365-s-12-32","title":"Treatment","mono":"<ul><li><b>HYDROCODONE <\/b><br\/><ul><li>Support: MANAGEMENT OF MILD TO MODERATE TOXICITY: Patients may only need observation. MANAGEMENT OF SEVERE TOXICITY: Administer oxygen and assist ventilation for respiratory depression. Naloxone is the antidote indicated for severe toxicity (respiratory or CNS depression). Orotracheal intubation for airway protection should be performed early in cases of obtundation and\/or respiratory depression that do not respond to naloxone, or in patients who develop severe acute lung injury.<\/li><li>Decontamination: PREHOSPITAL: Prehospital GI decontamination is generally not indicated because of the risk of CNS depression and aspiration. HOSPITAL: Consider activated charcoal if a patient presents soon after an ingestion and is not manifesting signs and symptoms of toxicity. Activated charcoal is generally not recommended in patients with significant signs of toxicity because of the risk of aspiration. Gastric lavage is not recommended as patients usually do well with supportive care.<\/li><li>Airway management: Administer oxygen and assist ventilation for respiratory depression. Orotracheal intubation for airway protection should be performed early in cases of obtundation and\/or respiratory depression that do not respond to naloxone, or in patients who develop severe acute lung injury.<\/li><li>Antidote: NALOXONE, an opioid antagonist, is the specific antidote. Naloxone can be given intravascularly, intramuscularly, subcutaneously, intranasally or endotracheally. The usual dose is 0.4 to 2.0 mg IV. In patients with suspected opioid dependence incremental doses of 0.2 mg IV should be administered, titrated to reversal of respiratory depression and coma, to avoid precipitating acute opioid withdrawal. Doses may be repeated every 2 to 3 minutes up to 20 mg. Very high doses are rarely needed, but may occasionally be necessary. A CONTINUOUS infusion may be necessary in patients that have ingested a large overdose or sustained release formulation. A suggested starting rate is two-thirds of the dose effective for initial reversal that is administered each hour; titrate as needed. DURATION of effect is usually 1-2 hours. Hydrocodone has a longer duration of effect, so it is necessary to observe the patient at least 3-4 hours after the last dose of naloxone to ensure that the patient does not have recurrent symptoms of toxicity. Naloxone can precipitate withdrawal in an opioid-dependent patients, which is usually not life-threatening; however it can be extremely uncomfortable for the patient.<\/li><li>Seizure: Seizures are very rare, but may be a result of hypoxia. Treatment includes ensuring adequate oxygenation, and administering intravenous benzodiazepines; propofol or barbiturates may be indicated, if seizures persist.<\/li><li>Acute lung injury: Acute lung injury can develop in a small proportion of patients after an acute opioid overdose, although there are no specific reports after hydrocodone overdose. The pathophysiology is unclear. Patients should be observed for 4 to 6 hours after overdose to evaluate for hypoxia and\/or the development of acute lung injury. Continuous oxygen therapy, pulse oximetry, PEEP and mechanical ventilation may be necessary.<\/li><li>Hypotensive episode: Hypotension is often reversed by naloxone. Initially treat with a saline bolus, if patient can tolerate a fluid load; then adrenergic vasopressors to raise mean arterial pressure.<\/li><li>Monitoring of patient: Monitor vital signs frequently, pulse oximetry, and continuous cardiac monitoring. Monitor for CNS and respiratory depression. Hydrocodone plasma levels are not clinically useful or readily available. Urine toxicology screens may confirm exposure, but are rarely useful in guiding therapy. Obtain a four hour acetaminophen and salicylate levels in a patient with a suspected overdose. Other routine lab work is usually not indicated, unless it is helpful to rule out other causes or if the diagnosis of hydrocodone toxicity is uncertain. Obtain a chest x-ray for persistent hypoxia. Consider a head CT and\/or lumbar puncture to rule out an intracranial mass, bleeding or infection, if the diagnosis is uncertain.<\/li><li>Enhanced elimination procedure: Hemodialysis and hemoperfusion are not of value.<\/li><li>Patient disposition: HOME CRITERIA: Respiratory depression may occur at doses just above a therapeutic dose, particularly in young children or those with underlying respiratory compromise. Children should be evaluated in the hospital and observed as they are generally opioid naive and may develop respiratory depression. Adults should be evaluated by a health care professional if they have received a higher than recommended (therapeutic) dose, especially if opioid naive. OBSERVATION CRITERIA: Patients with deliberate ingestions or who are symptomatic, or any pediatric ingestion above the therapeutic dose for age and weight should be sent to a healthcare facility for evaluation and treatment.  IMMEDIATE RELEASE: Observation for at least 4 hours, to ensure that peak plasma levels have been reached and there has been sufficient time for symptoms to develop. Patients who are treated with naloxone should be observed for 4 to 6 hours after the last dose, for recurrent CNS depression or acute lung injury. EXTENDED RELEASE: Observe for at least 7 to 12 hours (at therapeutic doses, Tmax for extended-release hydrocodone is 5 hours; for combination chlorpheniramine products: Tmax is 3.4 hours).  Peak concentrations are expected to be delayed after overdose, and symptoms may be delayed or prolonged. Patients who develop even moderate opioid effects or who require naloxone after ingestion of an extended-release product should be admitted. ADMISSION CRITERIA: IMMEDIATE RELEASE: Patients with significant, persistent central nervous system depression should be admitted to the hospital. A patient needing more than 2 doses of naloxone should be admitted as additional doses may be needed. Patients with coma, seizures, dysrhythmias, delirium, and those needing a naloxone infusion or who are intubated should be admitted to an intensive care setting. EXTENDED RELEASE: Patients who develop even moderate opioid effects or who require naloxone after ingestion of an extended-release product should be admitted. CONSULT CRITERIA: Consult a poison center or medical toxicologist for assistance in managing patients with severe toxicity or in whom the diagnosis is not clear.<\/li><\/ul><\/li><li><b>IBUPROFEN <\/b><br\/><ul><li>Support: MANAGEMENT OF MILD TO MODERATE TOXICITY: Most ibuprofen toxicity resolves with supportive care. Otherwise healthy patients with a history of ibuprofen poisoning generally require only supportive care and fluid and electrolyte replacement. MANAGEMENT OF SEVERE TOXICITY: Maintain an open airway and support ventilation. Treat seizures with benzodiazepines, hypotension with fluids and adrenergic vasopressors, and coma with intubation. Monitor ECG and arterial blood gases in patients with severe toxicity.<\/li><li>Decontamination: PREHOSPITAL: Activated charcoal can be given to patients with significant overdose (more than 200 mg\/kg) who are alert and can protect their airway. HOSPITAL: Activated charcoal binds ibuprofen and should be administered after significant overdose (more than 200 mg\/kg). Gastric lavage is rarely, if ever, indicated, as this drug is absorbed rapidly and severe toxicity is exceedingly rare.<\/li><li>Airway management: Endotracheal intubation should be considered for patients who present with CNS depression (rare).<\/li><li>Antidote: None<\/li><li>Hypotensive episode: IV 0.9% NaCl 10 to 20 ml\/kg, dopamine, norepinephrine.<\/li><li>Anaphylaxis: Mild: antihistamines; Severe: airway management, epinephrine, ECG monitoring, fluids.<\/li><li>Acidosis: Administer sodium bicarbonate 1 to 2 mEq\/kg intravenously for severe acidosis (pH less than 7.1). Monitor arterial pH and blood gases to guide bicarbonate therapy.<\/li><li>Monitoring of patient: Serum ibuprofen levels are not available in most hospital laboratories and are not necessary for clinical management. Measure serum electrolytes, creatinine and BUN. If significant CNS or respiratory toxicity is present, assess acid-base status. Obtain serum acetaminophen level. Monitor for gastrointestinal bleeding.<\/li><li>Enhanced elimination procedure: Ibuprofen is highly protein-bound; hemodialysis is unlikely to be effective.<\/li><li>Patient disposition: HOME CRITERIA: Asymptomatic children with inadvertent ingestions of less than 200 mg\/kg can be managed at home with milk or water dilution and observation. OBSERVATION CRITERIA: Symptomatic children, adults with deliberate ingestion, and children ingesting more than 200 mg\/kg should be referred to a health care facility for observation and treatment. Most patients who have ingested significant amounts of ibuprofen will manifest symptoms within 4 to 6 hours. ADMISSION CRITERIA: Patients who develop CNS depression, hypotension, acidosis, or gastrointestinal bleeding should be admitted.<\/li><\/ul><\/li><\/ul>"},{"id":"924365-s-12-33","title":"Range of Toxicity","mono":"<ul><li><b>HYDROCODONE<\/b><br\/>TOXICITY: Toxic dose is not established, and varies with the tolerance of the individual. A toddler with pneumonia died after receiving 15 mg hydrocodone over 9 hours. THERAPEUTIC DOSE: ADULTS: 5 to 10 mg hydrocodone every 4 to 6 hours. CHILDREN: 2 to 3 years or 12 to 15 kg: 1.875 mg hydrocodone every 4 to 6 hours; maximum daily dose is 11.25 mg hydrocodone; 4 to 6 years or 16 to 22 kg: 2.5 mg hydrocodone every 4 to 6 hours; maximum daily dose 15 mg hydrocodone; 7 to 9 years or 23 to 31 kg: 3.75 mg hydrocodone every 4 to 6 hours; maximum daily dose 22.5 mg hydrocodone; 10 to 13 years or 32 to 45 kg: 5 mg hydrocodone every 4 to 6 hours; maximum daily dose 30 mg hydrocodone; 14 years and up or 46 kg and up: 7.5 mg hydrocodone every 4 to 6 hours; maximum daily dose 45 mg hydrocodone.<br\/><\/li><li><b>IBUPROFEN<\/b><br\/>TOXICITY: Ingestions of less than 200 mg\/kg rarely cause significant toxicity; ingestions of greater than 400 mg\/kg may result in serious effects. ADULTS: Overdoses of up to 48 g have been well tolerated by healthy adults. An adult died following an overdose of 105 g of sustained-release ibuprofen. THERAPEUTIC DOSE: ADULT: OTC: 200 mg orally every 4 to 6 hours as needed; PRESCRIPTION: 400 to 800 mg orally every 6 to 8 hours as needed. PEDIATRIC: OTC: 5 to 10 mg\/kg.<br\/><\/li><\/ul>"}]},"13":{"id":"924365-s-13","title":"Clinical Teaching","mono":"<ul><li>Patient should avoid activities requiring mental alertness or coordination until drug effects are realized, as drug may cause dizziness or somnolence.<\/li><li>Female patients should avoid taking late in pregnancy, as drug may cause premature closure of the ductus arteriosus.<\/li><li>This drug may cause edema, constipation, dyspepsia, anemia, anxiety, or nervousness.<\/li><li>Instruct patients to report signs\/symptoms of serious gastrointestinal events such as bleeding, ulceration, or perforation of stomach or intestines. Elderly or debilitated patients may be at an increased risk for these adverse effects.<\/li><li>Patients with a cardiac history or on a long-term regimen are at an increased risk for adverse cardiovascular thrombotic events.  Advise patient to report signs\/symptoms of myocardial infarction or stroke.<\/li><li>Patient should also report signs\/symptoms of liver or renal dysfunction, excessive sedation, or respiratory depression.<\/li><li>Tell patient to report signs\/symptoms of a severe skin reaction such as Stevens-Johnson syndrome (flu-like symptoms, spreading red rash, or skin\/mucous membrane blistering) or toxic epidermal necrolysis (widespread peeling\/blistering of skin).<\/li><li>Tell patient it is best to take drug with food or milk.<\/li><li>Advise patients on long-term therapy to avoid sudden discontinuation of drug, as this may precipitate withdrawal symptoms.<\/li><li>Patient should not drink alcohol while taking this drug.<\/li><li>Advise patient not to take any other NSAIDs during treatment unless approved by healthcare provider.<\/li><\/ul>"}}}